Evidence map›Paper›PMID 35455329›Full record

ArticleVaccines2022

Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection.

Ilaria Vicenti, Monica Basso, Filippo Dragoni, Francesca Gatti, Renzo Scaggiante, Lia Fiaschi, Saverio G Parisi, Maurizio Zazzi

Abstract read
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ilaria VicentiDepartment of Medical Biotechnologies, University of Siena, Viale Bracci 16, 53100 Siena, Italy.ORCID 0000-0002-4306-2960
Monica BassoDepartment of Molecular Medicine, University of Padova, Via Gabelli, 63, 35100 Padova, Italy.
Filippo DragoniDepartment of Medical Biotechnologies, University of Siena, Viale Bracci 16, 53100 Siena, Italy.ORCID 0000-0002-8148-9914
Francesca GattiDepartment of Molecular Medicine, University of Padova, Via Gabelli, 63, 35100 Padova, Italy.
Renzo ScaggianteBelluno Hospital, Viale Europa, 22, 32100 Belluno, Italy.
Lia FiaschiDepartment of Medical Biotechnologies, University of Siena, Viale Bracci 16, 53100 Siena, Italy.
Saverio G ParisiDepartment of Molecular Medicine, University of Padova, Via Gabelli, 63, 35100 Padova, Italy.
Maurizio ZazziDepartment of Medical Biotechnologies, University of Siena, Viale Bracci 16, 53100 Siena, Italy.ORCID 0000-0002-0344-6281

Funding

EuCARE Project funded by the European Union´s Horizon Europe Re-search and Innovation Programme Grant Agreement No 101046016University of Padua DOR-2019University of Padua DOR-2020
6 · The paper itself

Abstract

We described the long-term decay of neutralizing antibody (NtAb) to the wild-type and Delta SARS-CoV-2 variant after three antigen stimulations (mild or asymptomatic natural infection followed by two doses of the BNT162b2 mRNA vaccine after a median of 296 days) in immunocompetent healthcare workers (HCWs). Live virus microneutralization against the B.1 and Delta SARS-CoV-2 variants was performed in VERO E6 cell cultures. The median NtAb titers for B.1 and Delta were comparable and highly correlated at both 20 and 200 days after the second vaccine dose in the 23 HCWs enrolled (median age, 46 years). A small group of naturally infected unvaccinated HCWs had comparable NtAb titers for the two strains after a median follow-up of 522 days from infection diagnosis. The NtAb response to the Delta VoC appears to follow the same long-term dynamics as the wild-type response regardless of the vaccinal boost; data collected after three antigen stimulations (natural infection followed by two doses of the BNT162b2 mRNA vaccine) may be helpful for tailoring the continuous monitoring of vaccine protection against SARS-CoV-2 variants over time.

Indexed as

BNT162b2 vaccineCOVID-19Deltaneutralizing antibodyvaccination

Identifiers

PMID35455329
PMCPMC9025891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.